KVIG Informative

Private equity healthcare buyouts hit a record $191 billion in 2025. In March 2026 alone, researchers tracked 8 buyouts, 68 add-on acquisitions, and 23 growth investments. Your doctor, your dentist, your hospice nurse — the odds are growing that a firm managing billions in investor capital now sits between you and your care.

The numbers are not subtle. Healthcare private equity dealmaking reached record levels in 2025, with disclosed deal value exceeding an estimated $191 billion — surpassing the previous high set in 2021, according to Bain and Company’s 2026 Global Healthcare Private Equity Report. Investors announced an estimated 445 buyouts, the second-highest annual total on record. The pace has not slowed entering 2026. The Private Equity Stakeholder Project, which tracks buyouts using PitchBook and press releases, documented 8 buyouts, 68 add-on acquisitions, and 23 growth investments in healthcare in March 2026 alone.

The sectors being consolidated read like a map of the American healthcare system. Dental care has been one of the busiest areas of private equity activity since 2023. Ophthalmology is accelerating — private equity firms see it as attractive because of an aging population, a high volume of procedures, and a fragmented market of independent practices ripe for rollup. Fertility clinics are being acquired at scale, with industry analysts describing the sector as recession-resistant due to the high out-of-pocket cost component. Home health and hospice companies are being bundled into regional and national platforms. Behavioral health, including youth services, autism treatment, and addiction recovery, has been a major consolidation target for years.

The mechanism is consistent across all of these sectors. A private equity firm acquires an initial platform practice, then gradually purchases smaller surrounding practices and rolls them up into a larger entity. As the platform grows, the firm can charge higher prices, reduce overhead through centralized administration, and eventually sell the whole platform to a larger buyer or take it public. The profit accrues to investors. The impact on patients is a different story.

The available research on what private equity ownership does to healthcare quality is not encouraging. Studies consistently show that consolidation among healthcare providers drives up the cost of care with little or no improvement in quality. Some studies show declines. At private equity-owned youth behavioral health companies, researchers have documented cost-cutting tactics including staff reductions, reliance on unlicensed personnel, and facility maintenance failures that have led to abuse, neglect, and unsafe conditions for children in their care. For-profit home health and hospice companies, which now dominate their sectors, have been linked to lower standards of care compared to nonprofit counterparts.

Private equity’s standard defense is that professional management and capital investment improve the operations of fragmented, underfunded practices. There are cases where that argument holds. But the structure of a leveraged buyout — where 60 to 90 percent of the acquisition price is financed with debt loaded onto the acquired company — creates a fundamentally different set of incentives than those of an independent physician or nonprofit health system. The debt has to be serviced. The fund has a defined timeline, typically five to seven years, to generate a return. The pressure those constraints create does not disappear just because the product being sold is medical care.

State and federal policymakers have begun paying closer attention. Regulatory and political scrutiny of private equity consolidation in healthcare has intensified, and buyers are responding with more disciplined, targeted acquisitions rather than broad-scale rollups. Joint ventures with nonprofit health systems have become an increasingly popular workaround — a structure that gives PE firms access to trusted brands and geographic markets while reducing the regulatory exposure that comes with outright acquisition. Lifepoint Health, owned by Apollo Global Management, operates at least 70 joint ventures with over 30 different nonprofit partners as of early 2026.

The scrutiny is real, but it has not stopped the deals. It has made them harder to see. Researchers at the Private Equity Stakeholder Project have described the phenomenon as stealth consolidation — acquisitions structured to avoid the disclosure thresholds that would trigger antitrust review, add-on deals too small to appear in standard merger databases, and joint ventures that blur the line between nonprofit mission and for-profit return. The healthcare system is being reorganized at a scale most patients cannot observe until they receive a bill, lose their preferred provider, or find that the clinic they relied on has been absorbed into a platform they have never heard of.